Conversion of BTU into shares and warrants of series TO3
The rights issue of units announced on 19 April 2022 (the “Rights Issue”) in Alzinova AB (publ) (“Alzinova” or the “Company”) has now been registered with the Swedish Companies Registration Office. The outcome of the Rights Issue was announced by press release on 15 June 2022.
The last day of trading with paid subscribed unit (BTU) is on 6 July 2022. The record date for the conversion is on 8 July 2022, after which BTU will be converted into shares and warrants of series TO3. Shares and warrants subscribed for in the Rights Issue is expected to be available on the subscriber's custodian/VP account on 12 July 2022. The first day of trading for the warrants of series TO3 is expected to be on 12 July 2022.
One (1) warrant of series TO3 entitles of subscription of one (1) new share in the Company during the exercise period that runs from and including 11 April 2023 to and including 25 April 2023. The subscription price per share will correspond to 70 percent of the volume-weighted average price (VWAP) of the Company's share on Nasdaq First North Growth Market during the period from and including 23 March 2023 to and including 5 April 2023, however not less than the quota value for the share (SEK 0.263 as of today) and not more than SEK 3.15. The total amount of warrants of series TO3 amounts to 12,967,612. If all warrants of series TO3 are exercised, the Company may receive at most approximately SEK 40.8 million.
ISIN code for shares: SE0007413455
ISIN code for BTU: SE0018012569
ISIN code for warrants of series TO3: SE0017833247
Advisors
Mangold Fondkommission AB is the financial advisor to Alzinova in connection with the Rights Issue. Fredersen Advokatbyrå AB is the legal advisor to the Company in connection with the Rights Issue.
For questions regarding the Rights Issue, please contact:
Mangold Fondkommission AB
Tel: +46 8 5030 1595
E-mail: emissioner@mangold.se
For more information, please contact:
Kristina Torfgård, CEO
Telephone: +46 70 846 79 75
E-mail: kristina.torfgard@alzinova.com
About Alzinova AB
Alzinova is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting neurotoxic amyloid-beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that target the toxic amyloid-beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Advisor on Nasdaq First North Growth Market is Corpura info@corpura.se +46 (0)768-532 822. For more information about Alzinova, please visit: www.alzinova.com.